Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0QX8X
|
|||
| Drug Name |
M2951
|
|||
| Synonyms |
evobrutinib; Evobrutinib; UNII-ZA45457L1K; ZA45457L1K; 1415823-73-2; 1-(4-(((6-amino-5-(4-phenoxyphenyl)pyrimidin-4-yl)amino)methyl)piperidin-1-yl)prop-2-en-1-one; 1-[4-[[[6-amino-5-(4-phenoxyphenyl)pyrimidin-4-yl]amino]methyl]piperidin-1-yl]prop-2-en-1-one; Evobrutinib [INN]; GTPL9752; SCHEMBL14165673; QUIWHXQETADMGN-UHFFFAOYSA-N; MSC2364447C; MSC-2364447C; ZINC205623965; AKOS032954004; CS-6303; MSC 2364447; HY-101215; A250 [WO2012170976]; N-[(1-acryloylpiperidin-4-yl)methyl]-5-(4-phenoxyphenyl)pyrimidine-4,6-diamine; 1-(4-((6-Amin
Click to Show/Hide
|
|||
| Indication | Multiple sclerosis [ICD-11: 8A40; ICD-9: 340] | Phase 2 | [1] | |
| Rheumatoid arthritis [ICD-11: FA20] | Phase 2 | [2] | ||
| Systemic lupus erythematosus [ICD-11: 4A40.0; ICD-9: 710] | Phase 1 | [2] | ||
| Company |
EMD Serono Rockland, MA
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C25H27N5O2
|
|||
| Canonical SMILES |
C=CC(=O)N1CCC(CC1)CNC2=NC=NC(=C2C3=CC=C(C=C3)OC4=CC=CC=C4)N
|
|||
| InChI |
1S/C25H27N5O2/c1-2-22(31)30-14-12-18(13-15-30)16-27-25-23(24(26)28-17-29-25)19-8-10-21(11-9-19)32-20-6-4-3-5-7-20/h2-11,17-18H,1,12-16H2,(H3,26,27,28,29)
|
|||
| InChIKey |
QUIWHXQETADMGN-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 1415823-73-2
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.